Home › Companies › Arbutus Biopharma Corporation › 2025-2026

Arbutus Biopharma Corporation 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Arbutus Biopharma Corporation’s Form 8-K, filed May 27, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.

8Ballot items
148Asset managers
1,267Fund votes
May 26, 2026Meeting date

Results at a glance

Meeting of May 26, 2026: 8 items on Arbutus Biopharma Corporation’s Form 8-K, filed May 27, 2026: 3 approved · 5 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arbutus Biopharma Corporation in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Arbutus Biopharma Corporation

These tallies are Arbutus Biopharma Corporation’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 27, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arbutus Biopharma Corporation — official shareholder meeting results, meeting held May 26, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Lindsay Androski, JD, MBA, CFA	136,780,089	--	--	9,693,538	22,829,831	93%	Not verified	—
Elect Director: Robert Alan Beardsley	138,456,756	--	--	8,016,871	22,829,831	95%	Not verified	—
Elect Director: Joseph Bishop	137,372,240	--	--	9,101,387	22,829,831	94%	Not verified	—
Elect Director: Matthew Gline	126,670,273	--	--	19,803,354	22,829,831	86%	Not verified	—
Elect Director: Roger Sawhney, MD	139,299,405	--	--	7,174,222	22,829,831	95%	Not verified	—
2. Approved the adoption of the 2026 Plan	138,877,189	7,408,185	188,253	--	22,829,831	95%	Approved	—
3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular	137,629,207	8,331,760	512,660	--	22,829,831	94%	Approved	—
4. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026	164,372,596	2,123,916	2,806,946	--	--	99%	Approved	—

Source: Arbutus Biopharma Corporation, Form 8-K, filed with the SEC on May 27, 2026 — read the filing on EDGAR.

How asset managers voted at the Arbutus Biopharma Corporation 2025-2026 meeting

Each item below shows how the 148 asset managers that disclosed a Arbutus Biopharma Corporation vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Joseph Bishop

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 137,372,240WITHHELD: 9,101,387

Details: description as filed, official tally, votes by 37 asset managers

Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Joseph Bishop

Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Joseph Bishop”): 137,372,240 for, 9,101,387 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 27,898,121 for, 275,804 withheld, 28 abstained.

FOR

FOR: 27,898,121ABSTAIN: 28WITHHOLD: 275,804

Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	7,987,215	28	6,273	For
Morgan Stanley	6,182,656	0	0	For
BlackRock	4,907,707	0	0	For
State Street	2,680,508	0	0	For
Fidelity	1,756,377	0	0	For
Equitable	1,651,258	0	0	For
Charles Schwab	1,399,892	0	0	For
TIAA	0	0	256,883	Withhold
QUANTITATIVE MASTER SERIES LLC	248,061	0	0	For
Invesco	148,531	0	0	For
Lincoln Financial	102,200	0	0	For
Goldman Sachs	99,139	0	0	For
ProShares	86,900	0	0	For
AIG/SunAmerica	80,331	0	0	For
Northern Trust	75,298	0	0	For
Global X	70,920	0	0	For
ETFis Series Trust I	57,895	0	0	For
Pacific Life	51,981	0	0	For
Brighthouse	48,336	0	0	For
John Hancock	42,237	0	0	For
Nationwide	40,001	0	0	For
Bridge Builder Trust	32,901	0	0	For
Voya	28,676	0	0	For
Direxion Shares ETF Trust	28,437	0	0	For
DWS	21,573	0	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

2. Elect Director: Lindsay Androski, JD, MBA, CFA

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 136,780,089WITHHELD: 9,693,538

Details: description as filed, official tally, votes by 37 asset managers

Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Lindsay Androski, JD, MBA, CFA”): 136,780,089 for, 9,693,538 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 28,161,275 for, 12,648 withheld, 30 abstained.

FOR

FOR: 28,161,275ABSTAIN: 30WITHHOLD: 12,648

Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,993,486	30	For
Morgan Stanley	6,182,656	0	For
BlackRock	4,907,707	0	For
State Street	2,680,508	0	For
Fidelity	1,756,377	0	For
Equitable	1,651,258	0	For
Charles Schwab	1,399,892	0	For
TIAA	256,883	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	For
Invesco	148,531	0	For
Lincoln Financial	102,200	0	For
Goldman Sachs	99,139	0	For
ProShares	86,900	0	For
AIG/SunAmerica	80,331	0	For
Northern Trust	75,298	0	For
Global X	70,920	0	For
ETFis Series Trust I	57,895	0	For
Pacific Life	51,981	0	For
Brighthouse	48,336	0	For
John Hancock	42,237	0	For
Nationwide	40,001	0	For
Bridge Builder Trust	32,901	0	For
Voya	28,676	0	For
Direxion Shares ETF Trust	28,437	0	For
DWS	21,573	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

3. Elect Director: Matthew Gline

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%

FOR: 126,670,273WITHHELD: 19,803,354

Details: description as filed, official tally, votes by 37 asset managers

Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Matthew Gline”): 126,670,273 for, 19,803,354 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 22,059,662 for, 925,593 withheld, 5,188,698 abstained.

FORABSTAIN

FOR: 22,059,662ABSTAIN: 5,188,698WITHHOLD: 925,593

Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	7,987,214	29	6,273	For
Morgan Stanley	6,182,656	0	0	For
BlackRock	0	4,907,707	0	Abstain
State Street	2,680,508	0	0	For
Fidelity	1,693,046	0	63,331	For
Equitable	1,404,832	0	246,426	Mixed
Charles Schwab	1,399,892	0	0	For
TIAA	0	0	256,883	Withhold
QUANTITATIVE MASTER SERIES LLC	0	248,061	0	Abstain
Invesco	0	0	148,531	Withhold
Lincoln Financial	102,200	0	0	For
Goldman Sachs	99,139	0	0	For
ProShares	86,900	0	0	For
AIG/SunAmerica	80,331	0	0	For
Northern Trust	75,298	0	0	For
Global X	0	0	70,920	Withhold
ETFis Series Trust I	57,895	0	0	For
Pacific Life	0	0	51,981	Withhold
Brighthouse	48,336	0	0	For
John Hancock	42,237	0	0	For
Nationwide	0	0	40,001	Withhold
Bridge Builder Trust	0	32,901	0	Abstain
Voya	28,676	0	0	For
Direxion Shares ETF Trust	28,437	0	0	For
DWS	21,573	0	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

4. Elect Director: Robert Alan Beardsley

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 138,456,756WITHHELD: 8,016,871

Details: description as filed, official tally, votes by 37 asset managers

Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Robert Alan Beardsley”): 138,456,756 for, 8,016,871 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 28,173,929 for, 24 abstained.

FOR

FOR: 28,173,929ABSTAIN: 24

Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,993,492	24	For
Morgan Stanley	6,182,656	0	For
BlackRock	4,907,707	0	For
State Street	2,680,508	0	For
Fidelity	1,756,377	0	For
Equitable	1,651,258	0	For
Charles Schwab	1,399,892	0	For
TIAA	256,883	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	For
Invesco	148,531	0	For
Lincoln Financial	102,200	0	For
Goldman Sachs	99,139	0	For
ProShares	86,900	0	For
AIG/SunAmerica	80,331	0	For
Northern Trust	75,298	0	For
Global X	70,920	0	For
ETFis Series Trust I	57,895	0	For
Pacific Life	51,981	0	For
Brighthouse	48,336	0	For
John Hancock	42,237	0	For
Nationwide	40,001	0	For
Bridge Builder Trust	32,901	0	For
Voya	28,676	0	For
Direxion Shares ETF Trust	28,437	0	For
DWS	21,573	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

5. Elect Director: Roger Sawhney, MD

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 139,299,405WITHHELD: 7,174,222

Details: description as filed, official tally, votes by 37 asset managers

Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Roger Sawhney, MD”): 139,299,405 for, 7,174,222 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 37 asset managers below reported 28,173,931 for, 22 abstained.

FOR

FOR: 28,173,931ABSTAIN: 22

Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,993,494	22	For
Morgan Stanley	6,182,656	0	For
BlackRock	4,907,707	0	For
State Street	2,680,508	0	For
Fidelity	1,756,377	0	For
Equitable	1,651,258	0	For
Charles Schwab	1,399,892	0	For
TIAA	256,883	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	For
Invesco	148,531	0	For
Lincoln Financial	102,200	0	For
Goldman Sachs	99,139	0	For
ProShares	86,900	0	For
AIG/SunAmerica	80,331	0	For
Northern Trust	75,298	0	For
Global X	70,920	0	For
ETFis Series Trust I	57,895	0	For
Pacific Life	51,981	0	For
Brighthouse	48,336	0	For
John Hancock	42,237	0	For
Nationwide	40,001	0	For
Bridge Builder Trust	32,901	0	For
Voya	28,676	0	For
Direxion Shares ETF Trust	28,437	0	For
DWS	21,573	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

6. 2. Approved the adoption of the 2026 Plan

Official result Fund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%

FOR: 138,877,189AGAINST: 7,408,185

Details: description as filed, official tally, votes by 39 asset managers

Description as filed by funds: TO APPROVE THE ADOPTION OF THE ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN;

Arbutus Biopharma Corporation’s own tally for this item (“2. Approved the adoption of the 2026 Plan”): 138,877,189 for, 7,408,185 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) approved the adoption of the 2026 Plan”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 37 asset managers voting on “TO APPROVE THE ADOPTION OF THE ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN;” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	7,980,229	13,287	For
Morgan Stanley	6,182,656	0	For
BlackRock	4,907,707	0	For
State Street	2,680,508	0	For
Fidelity	1,756,377	0	For
Equitable	1,651,258	0	For
Charles Schwab	1,399,892	0	For
TIAA	256,883	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	For
Invesco	0	148,531	Against
Lincoln Financial	102,200	0	For
Goldman Sachs	99,139	0	For
ProShares	86,900	0	For
AIG/SunAmerica	80,331	0	For
Northern Trust	75,298	0	For
Global X	70,920	0	For
ETFis Series Trust I	57,895	0	For
Pacific Life	51,981	0	For
Brighthouse	48,336	0	For
John Hancock	42,237	0	For
Nationwide	40,001	0	For
Bridge Builder Trust	32,901	0	For
Voya	28,676	0	For
Direxion Shares ETF Trust	28,437	0	For
DWS	21,573	0	For

Fund voting reports, all 37 managers: 28,011,325 for, 162,628 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “TO APPROVE THE ADOPTION OF THE ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN;” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Deltroit Asset Management (UK) LLP	800,000	0	0	0	For
Rangeley Capital, LLC	353,501	0	0	0	For

Institutional-manager reports, all 2 managers: 1,153,501 for.

7. 3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed…

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%

FOR: 137,629,207AGAINST: 8,331,760

Details: description as filed, official tally, votes by 148 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and

Arbutus Biopharma Corporation’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular”): 137,629,207 for, 8,331,760 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 37 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in ” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	7,993,489	25	1	For
Morgan Stanley	6,182,656	0	0	For
BlackRock	4,907,707	0	0	For
State Street	2,680,508	0	0	For
Fidelity	1,756,377	0	0	For
Equitable	1,651,258	0	0	For
Charles Schwab	1,399,892	0	0	For
TIAA	256,883	0	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	0	For
Invesco	0	148,531	0	Against
Lincoln Financial	102,200	0	0	For
Goldman Sachs	99,139	0	0	For
ProShares	86,900	0	0	For
AIG/SunAmerica	80,331	0	0	For
Northern Trust	75,298	0	0	For
Global X	70,920	0	0	For
ETFis Series Trust I	57,895	0	0	For
Pacific Life	51,981	0	0	For
Brighthouse	48,336	0	0	For
John Hancock	42,237	0	0	For
Nationwide	40,001	0	0	For
Bridge Builder Trust	32,901	0	0	For
Voya	28,676	0	0	For
Direxion Shares ETF Trust	28,437	0	0	For
DWS	21,573	0	0	For

Fund voting reports, all 37 managers: 28,025,395 for, 148,556 against, 1 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 123 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in ” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Against	Vote
Morgan Stanley	25,251,082	0	For
Two Seas Capital LP	14,717,397	0	For
State Street	5,661,682	23,979	For
BlackRock	4,883,883	33,074	For
Legal & General Investment Management Ltd	2,370,471	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,117,957	0	For
ADAR1 Capital Management, LLC	1,627,678	0	For
Charles Schwab	1,400,489	0	For
Rubric Capital Management LP	1,265,390	0	For
Vanguard	1,242,762	0	For
Northern Trust	880,731	16,948	For
Deltroit Asset Management (UK) LLP	800,000	0	For
UBS	0	741,177	Against
Rangeley Capital, LLC	353,501	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	301,741	0	For
Wellington	290,344	0	For
Nuveen	259,017	0	For
MELLON INVESTMENTS Corp	256,841	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	216,239	0	For
Western Standard LLC	215,038	0	For
T. Rowe Price	186,890	0	For
Fidelity	140,917	0	For
Hudson Bay Capital Management LP	140,384	0	For
KENNEDY CAPITAL MANAGEMENT LLC	108,486	30,087	Mixed
AllianceBernstein	127,340	0	For

Institutional-manager reports, all 123 managers: 66,098,880 for, 1,011,414 against, 700 not voted. Showing the 25 largest; see all in the interactive database.

8. 4. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%

FOR: 164,372,596AGAINST: 2,123,916

Details: description as filed, official tally, votes by 37 asset managers

Description as filed by funds: TO APPROVE THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Arbutus Biopharma Corporation’s own tally for this item (“4. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 164,372,596 for, 2,123,916 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(4) approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 28,173,946 for, 3 against, 5 abstained.

FOR

FOR: 28,173,946AGAINST: 3ABSTAIN: 5

Largest asset managers voting on “TO APPROVE THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE F” at Arbutus Biopharma Corporation, 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	7,993,509	3	5	For
Morgan Stanley	6,182,656	0	0	For
BlackRock	4,907,707	0	0	For
State Street	2,680,508	0	0	For
Fidelity	1,756,377	0	0	For
Equitable	1,651,258	0	0	For
Charles Schwab	1,399,892	0	0	For
TIAA	256,883	0	0	For
QUANTITATIVE MASTER SERIES LLC	248,061	0	0	For
Invesco	148,531	0	0	For
Lincoln Financial	102,200	0	0	For
Goldman Sachs	99,139	0	0	For
ProShares	86,900	0	0	For
AIG/SunAmerica	80,331	0	0	For
Northern Trust	75,298	0	0	For
Global X	70,920	0	0	For
ETFis Series Trust I	57,895	0	0	For
Pacific Life	51,981	0	0	For
Brighthouse	48,336	0	0	For
John Hancock	42,237	0	0	For
Nationwide	40,001	0	0	For
Bridge Builder Trust	32,901	0	0	For
Voya	28,676	0	0	For
Direxion Shares ETF Trust	28,437	0	0	For
DWS	21,573	0	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Largest Arbutus Biopharma Corporation shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 197,537,710 shares outstanding at the time of that meeting.

Fund voting reports: top Arbutus Biopharma Corporation shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	4.05%
2	Morgan Stanley	3.13%
3	BlackRock	2.48%
4	State Street	1.36%
5	Fidelity	0.89%
6	Equitable	0.84%
7	Charles Schwab	0.71%
8	TIAA	0.13%
9	QUANTITATIVE MASTER SERIES LLC	0.13%
10	Invesco	0.08%

Institutional-manager reports: top Arbutus Biopharma Corporation shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Morgan Stanley	12.78%
2	Two Seas Capital LP	7.45%
3	State Street	2.88%
4	BlackRock	2.49%
5	Legal & General Investment Management Ltd	1.20%
6	GEODE CAPITAL MANAGEMENT, LLC	1.07%
7	ADAR1 Capital Management, LLC	0.82%
8	Charles Schwab	0.71%
9	Rubric Capital Management LP	0.64%
10	Vanguard	0.63%

Reported Arbutus Biopharma Corporation holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Arbutus Biopharma Corporation holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Matthew Gline	19.67%	DEF14A
Roivant Sciences Ltd.	19.67%	DEF14A
Morgan Stanley	13.52%	13F
Entities affiliated with Morgan Stanley	13.12%	DEF14A
Two Seas Capital LP	9.39%	13G
Entities affiliated with Whitefort Capital Management, LP	7.56%	DEF14A
BlackRock	6.56%	13F
Entities affiliated with Two Seas Capital LP	6.37%	DEF14A
Entities affiliated with Blackrock, Inc.	5.26%	DEF14A
Vanguard Group	4.68%	13F

Percentages above are of 197,537,710 shares outstanding, as reported by Arbutus Biopharma Corporation on its Form 10-Q dated May 11, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arbutus Biopharma Corporation’s 10-Q dated May 11, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Arbutus Biopharma Corporation's shareholder meeting held May 26, 2026, in the 2025-2026 proxy season, 148 asset managers reported how they voted on 8 ballot items in their SEC Form N-PX filings, covering 1,267 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — Arbutus Biopharma Corporation's filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Arbutus Biopharma Corporation's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 27, 2026.

Arbutus Biopharma Corporation proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.